Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2023)

Historic Change in Accured Expenses for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $946000.0.

  • Candel Therapeutics' Change in Accured Expenses rose 11747.13% to $946000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$301000.0, marking a year-over-year decrease of 12379.45%. This contributed to the annual value of $757000.0 for FY2024, which is 35149.5% up from last year.
  • As of Q4 2023, Candel Therapeutics' Change in Accured Expenses stood at $946000.0, which was up 11747.13% from -$85000.0 recorded in Q3 2023.
  • Over the past 5 years, Candel Therapeutics' Change in Accured Expenses peaked at $1.4 million during Q4 2020, and registered a low of -$1.8 million during Q1 2023.
  • Over the past 4 years, Candel Therapeutics' median Change in Accured Expenses value was $310500.0 (recorded in 2022), while the average stood at $198714.3.
  • As far as peak fluctuations go, Candel Therapeutics' Change in Accured Expenses skyrocketed by 51060.61% in 2021, and later crashed by 208888.89% in 2023.
  • Candel Therapeutics' Change in Accured Expenses (Quarter) stood at $1.4 million in 2020, then plummeted by 48.24% to $719000.0 in 2021, then crashed by 39.5% to $435000.0 in 2022, then soared by 117.47% to $946000.0 in 2023.
  • Its Change in Accured Expenses was $946000.0 in Q4 2023, compared to -$85000.0 in Q3 2023 and $628000.0 in Q2 2023.